XL-228 is a third generation inhibitor of Abl that shows efficacy in a variety of cell lines, including those exhibiting T315I mutations. XL-228 displays anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for chronic myelogenous leukemia (CML).
| Cas No. | 898280-07-4 |
|---|---|
| Purity | ≥98% |
| Formula | C22H31N9O |
| Formula Wt. | 437.54 |
| IUPAC Name | 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| Solubility | Soluble in DMSO |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8(10):905-21. PMID: 18673174.
